Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Xcel Energy Inc (XEL) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Xcel Energy (XEL) trades at $74.64, up 0.63% with a bullish technical signal. The stock shows strong fundamentals with 2025 revenue of $14.67B and net income of $2.02B (13.75% margin). Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus buy rating with a $90.50 price target. The company benefits from rising power demand and a $60B capital expenditure plan focused on infrastructure and data center growth.

XEL offers solid growth potential driven by utility infrastructure investment and data center demand, with 62.96% analyst buy ratings supporting upside to $90.50. Key risks include wildfire liabilities, regulatory challenges, and high capital spending requirements. The stock presents a balanced opportunity for dividend-focused investors seeking regulated utility exposure with growth catalysts.